Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Melanoma 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 62Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 23Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × poly(I).poly(c12,U) × Clear all
NCT01312389 2021-11-15

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Terminated
3 enrolled 4 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡